skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBreast CancerBreast CancerSCE Medical Oncology

A 60-year-old woman with ER+/HER2- metastatic breast cancer responds to first-line fulvestrant + CDK4/6 inhibitor for 20 months then progresses. No PIK3CA or BRCA mutation. ECOG PS 1. What is the most appropriate next therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Single-agent capecitabine or paclitaxel

After progression on endocrine + CDK4/6 inhibitor without actionable mutations, chemotherapy is appropriate for rapidly progressive disease. Exemestane + everolimus is an alternative for slower progression.

Reference: ESMO 2024 Metastatic Breast Cancer Living Guideline